Candel Therapeutics Reports Extended Survival in NSCLC: 50% of Patients Survive Over 24 Months with CAN-2409 After Immune Checkpoint Failure
Market Chameleon (Tue, 17-Mar 8:43 AM)
Candel Therapeutics Targets $100 Million Public Offering to Accelerate Cancer Therapy Development
Market Chameleon (Fri, 20-Feb 7:31 AM)
